

Curriculum Vitae
Patrick A. Oliver, MD

CONTACT INFORMATION:

Name Patrick A. Oliver, MD

Office Addresses **Mind Peace, LLC**

MindPeace Clinic – Arlington
1600 Wilson Blvd, Suite 320
Arlington, VA 22209 USA
Telephone 703 340 1454
Fax # 703 832 9288

MindPeace Clinic – Richmond
7603 Forest Ave, Suite 301
Richmond, VA 23229 USA
Telephone 804 286 0082
Fax # 703 832 9288

MindPeace Clinic – Norfolk
6275 E. Virginia Beach Blvd, Suite 303
Norfolk, VA 23502 USA
Telephone 757 337 1525
Fax # 703 832 9288

Email POliverMD@MindPeaceClinics.com

PROFESSIONAL BACKGROUND

Group and Hospital Affiliations, MD

- Mind Peace Clinics – *Medical Director*, Arlington, Norfolk & Richmond, VA 1/2017 – Present
- **Ketamine Therapeutics Treatments**
 - Founder of Mind Peace, LLC.,
 - Administered thousands of Ketamine infusions to hundreds of patients
 - Treating patients with Ketamine & Esketamine for the following indications:
 - Suicidal Ideation
 - Mood Disorders (Depression, Anxiety & Obsessive-Compulsive Disorder (OCD))
 - Complex Regional Pain Syndrome (CRPS) & Reflex Sympathetic Dystrophy (RSD)
 - Chronic Headaches (Migraines, Trigeminal Neuralgia)
 - Post-Traumatic Stress Disorder (PTSD)
- Southside Regional Medical Center (SRMC) – Petersburg, VA 6/2014 – Present
- Infusion Solutions, LLC - *Medical Director*, Richmond, VA 1/2020 – 4/2022
- Clinical Research Partners, LLC – *Investigator*, Richmond, VA 9/2018 – 1/2022
- Medical College of Virginia (MCV) Emergency Department – Richmond, VA 4/2014 – 12/2017
- Bon Secours Memorial Regional Medical Center (MRMC) – Mechanicsville, VA 8/2010 – 1/2015
- Bon Secours Mary Immaculate Hospital (MIH) – Newport News, VA 9/2010 – 7/2014
- Rappahannock General Hospital (RGH) – Kilmarnock, VA 2/2011 – 6/2013
- Centra Southside Community Hospital (CES) – Farmville, VA 10/2010 – 1/2012
- St. Luke’s Hospital and Health Network (SLHN) – Bethlehem, PA 6/2007 – 6/2010

Certifications, Licenses & Training

- NPI Number: **1154518751**
- Commonwealth of Virginia – Medical Physician & Surgeon License – **Active: 0101247379**
- CITI Collaborative Institutional Training Initiative – web-based training
- Curriculum: Good Clinical Practice, Human Subjects in Research, HIPAA

CV – PATRICK A. OLIVER, MD
Updated: 17 MAR 2021

- American Board of Emergency Medicine – *Diplomat*
- Controlled Substance Registration Certificates, Drug Enforcement Administration – Active
- Commonwealth of Pennsylvania – Medical Physician & Surgeon License – Inactive
- Medical Command Physician – Pennsylvania Department of Health
- Advanced Ultrasound Course – American Academy of Emergency Medicine
- Advanced Airway Course – Lehigh Valley Hospital – Allentown, PA
- HIPPA Course Certification
- Child Abuse Course Certification
- Commonwealth of Virginia – Emergency Vehicle Operators Course Certificate (EVOC)
- Advanced Cardiac Life Support (ACLS)
- Advanced Trauma Life Support (ATLS)
- Pediatric Advanced Life Support (PALS)

Academic Affiliation

- **Medical College of Virginia, Virginia Commonwealth University**
 - *Assistant Clinical Professor*, Department of Internal Medicine 8/2012 – 12/2016
 - *Clinical Instructor*, Department of Emergency Medicine 4/2014 – 12/2017

Professional Associations

- Medical Society of Virginia (MSV) 2004 – Present
- Richmond Academy of Medicine (RAM) 2004 – Present
- American Academy of Emergency Medicine (AAEM) 2008 – Present
- American Society of Ketamine Physicians (ASKP) 2017 – Present
- Washington Psychiatric Society (WSP) (Associate Member) 2017 – Present
- American Medical Association (AMA) 2003 – 2011
- American College of Emergency Physicians (ACEP) 2006 – 2010
- Society of Academic Emergency Medicine (SAEM) 2009 – 2010
- Pennsylvania College of Emergency Physicians (PACEP) 2007 – 2010
- Virginia College of Emergency Physicians (VACEP) 2005 – 2007

BUSINESS EXPERIENCE

Pentico Solutions, Inc. 10/2001 – 5/2003

- **Consultant – Centocor, Inc** (subsidiary of Johnson and Johnson) – Malvern, Pennsylvania
 - Designed and implemented a custom web-based database tracking system, QUEST, for the Research and Development Global Contracting (RDGC) Function
 - Advised and assisted a Process Excellence (Six Sigma methodology) effort for RDGC
 - Implemented a Project Management Methodology (PMM) for RDGC Leadership that was consistent with the overall Centocor PMM & the Project Management Institute’s Body of Knowledge (PMBOK)
 - Represented the RDGC prospective within the Project Management and Portfolio Planning (PM&PP) Department Working Group for a multi-Johnson & Johnson Enterprise Resource and Project Management System (ERPM), which is an OPX2 based Operating System
 - Managed contracts and coordinated negotiations for four (Phase II & III) Clinical Trials
- **Consultant – AstraZeneca Pharmaceuticals, LP** – Wilmington, Delaware
 - Led design and development of the Strategic Staffing Process Initiative Presentation
 - Drafted the process for policy development within Human Resources from industry best practices

KPMG, LLP – Public Services Practice 10/1998 – 5/2001

- **Consultant – Federal Services** – Crystal City & Pentagon, Virginia
 - Led Performance Based Budget Cycle Implementation for the US Army
 - Developed Performance Based Budget for the Foreign Military Sales Administrative Trust Fund
 - Facilitated development of security cooperation performance metrics and review methodology

- Acted as technical lead for multifaceted e-Learning solution to educate decision makers and train participants
- Facilitated development and design of standardized budget submission templates for all participation agencies
- **Consultant – State and Local Government – Sacramento, California**
 - Aided in planning and implementation of the California Board of Control's Strategic Business Plan, which utilized the Balanced Scorecard Approach
 - Led an organization review and analysis of the Administrative Unit for the County of Sacramento Transportation Division
 - Conducted a thorough management review of the Sacramento County Probation Department
 - Assisted in the performance audit of the Administrative Law Bureau of the California Department of Insurance (CDI)
 - Assisted in the development of the CDI Holocaust Restitution Effort Budget Change Proposal
 - Compiled statistics and drafted the requisite Status Report regarding the CDI's Holocaust Restitution Effort to the California Legislature
 - Established and implemented the internal process and procedures for performing Market Conduct Examinations for CDI
 - Participated in the on-site evaluation of an insurance company's refund process pursuant to California Proposition 103 on behalf of CDI
 - Developed sections of a training seminar for the Idaho State Department of Health and Human Services' Division of Medicaid Quality Insurance and Management Committees
 - Performed Y2K systemic review for the City of Sacramento's Public Works and Administration Departments

EMERGENCY MEDICAL SERVICES EXPERIENCE

- **Lakeside Volunteer Rescue Squad** 4/2015 – 4/2020
 - Operational Medical Director (OMD)
- **Tuckahoe Volunteer Rescue Squad** 11/1994 – 6/2007
 - Advanced Life Support Provider & Preceptor
 - Crew Chief – Pump Road Station
 - Bicycle Team Founding Member
 - Uniform Committee Chair
 - Vehicular Extrication Attendant
- **Commonwealth of Virginia, Office of Emergency Medical Services** 1997
 - Facilitated the execution of a "Table Top" exercise of Emergency Response to a Nuclear Detonation of at a Central Virginia Theme Park with Federal, State and Local Agencies and Organizations
 - Reviewed and Amended Commonwealth of Virginia Emergency Services Center Standard Operating Procedures and Response Scenarios
 - Lead tactical evaluation of Triennial Emergency Services Drill at Richmond International Airport
- **Commonwealth of Virginia, Office of Emergency Medical Services** 1996 – 1998
 - Fairbanks RJ, Goyal M, Gehr TWB. Renal Failure & Dialysis Patients. VEMS-TV ("EMSAT" educational program). Office of Emergency Medical Services, Virginia Department of Health, Richmond, VA. Broadcast and video release date: December 1998. Coy, T.
 - Gun Shot Wounds in Rural Environments. VEMS-TV ("EMSAT" educational program). Office of Emergency Medical Services, Virginia Department of Health, Richmond, VA. Broadcast and video release date: October, 1996.

ACADEMIC BACKGROUND

Education

- **Emergency Medicine Residency Program – Saint Luke's Hospital**, Bethlehem, Pennsylvania
 - Allopathic Emergency Medicine Program 6/2007 – 6/2010
- **Medical College of Virginia – Virginia Commonwealth University**, Richmond, Virginia

- Doctor of Medicine 8/2003 – 5/2007
- **College of General Studies – University of Pennsylvania**, Philadelphia, Pennsylvania
 - Post Baccalaureate Pre-Health Program 5/2001 – 5/2003
- **Jepson School of Leadership Studies – University of Richmond**, Richmond, Virginia
 - Bachelor of Arts 8/1994 – 5/1998
 - Double majors in Leadership Studies and Speech Communication

Awards & Honors

- “Going the Extra Mile!” Recognition – St. Luke’s Hospital 2007
- Dean’s List – University of Richmond Spring 1998
- Greek Unsung Hero Award – University of Richmond’s Interfraternity Council 1998
- Intermediate Honors – University of Richmond Spring 1996
- Sophomore Outstanding Leadership Award – ODK December 1996
- Eagle Scout Award with Bronze and Gold Palms March 1992

Academic Works (Lectures, Papers, and Presentations)

- Arias, A., Fein, R., Oliver, P. An Exploratory Machine Learning-Based Approach to Predicting Outcomes with Intravenous Racemic Ketamine Treatment of Major Depressive Disorder American College of Neuro Psychopharmacology (Poster Presentation) 4 December 2022
- Oliver, P. et al. Clinical Effectiveness of Intravenous Racemic Ketamine Infusions in a Large Community Sample of Patients with Treatment-Resistant Depression, Suicidal Ideations, and Generalized Anxiety Symptoms: A Retrospective Chart Review 12 September 2022
- Oliver, P. Clinical Effectiveness of Intravenous Racemic Ketamine Infusions in a Large Community Sample 11 June 2022
American Society of Ketamine Physicians, 2022 Annual Meeting
- Oliver, P. Ketamine for the Treatment of Mood Disorders and Suicidal Ideation 4 March 2021
Riverside/VCU Family Medicine Residency Program: Grand Rounds
- Oliver, P. How does Ketamine Treat Depression 9 September 2020
EVMS Psychiatry Residency Program: Grand Rounds
- Oliver, P. Ketamine for the Treatment of Mood Disorders & Suicidal Ideation. 25 September 2018
University of Virginia Grand Rounds
- Oliver, P. Pre-Hospital Emergency Airways. 13 May 2015
VCU Emergency Medicine Residency Program: Grand Rounds
- Oliver, P. Doctors and Dollars. AAEM Scientific Assembly: PK Lecture 3 March 2015
- Oliver, P. Doctors and Dollars. M2 Orientation for MCV School of Medicine 15 July 2012
- Oliver P, Ornato J, Regan C, Brown W, Stolzhus J: Correlation Between Heart Rate in Pre-Hospital Patients with Atrial Fibrillation with Rapid Ventricular Response and Blood Serum Magnesium Levels 15 February 2010
- Oliver, P. Case Presentation: Deep Vein Thrombosis 27 August 2009
- St. Luke’s Emergency Medicine Residency Program Grand Rounds
- Oliver P, EMS Presentation: Prehospital Hypothermia 23 October 2008
- Combined St. Luke’s Emergency Medicine Residency Program Grand Rounds and Lehigh Valley Emergency Medical Services Lecture
- Oliver P, Eberhardt M, Clay E: Attending Social Gatherings and Grand Rounds Has No Effect on the Opinions of Candidates Interviewing for Emergency Medicine Residency Positions.
 - AAEM – 15th Annual Scientific Assembly 2 March 2009
 - St. Luke’s Hospital and Health Network Research Symposium 18 June 2009
- Oliver, P. Street Drugs: What Basic Life Support Providers Need to Know 10 November 2008
- Lehigh University Emergency Medical Service Response Team Lehigh University
- Oliver, P. Trauma Case Presentation: Central Spinal Cord Injury 21 January 2009
- St. Luke’s Hospital Trauma Conference
 - Oliver, P. Shock and Resuscitation SLHN Surgical Critical Care Conference 23 July 2009
 - Oliver, P. Sepsis and Septic Shock SLHN Surgical Critical Care Conference 16 July 2009
- Oliver, P. Case Presentation: Aortic Thromboembolism 28 November 2007
- St. Luke’s Emergency Medicine Program Grand Rounds

- Oliver, P. Case Presentation: Ectopic Pregnancy 1 November 2007
- St. Luke's Emergency Medicine Program Grand Rounds
- MCV Emergency Medicine Residency Program Teaching Conference
- Oliver, P. Case Presentation: Hyperkalemia September 2006

PERSONAL

Activities

- Richmond Ambulance Authority (RAA) – Special Medical Advisor to UREMS 2011 – 2020
- Ducatista 2005 – Present
- Scuba Diving (NAUI Certification 1997) 1997 – Present
- MCV Class of 2007 Student Government – Alumni Representative 2004 – 2007
- MCV Alumni Annual Fund – Chair and Vice Chair 2004 – 2005
- Emergency Medical Resident's Association – MCV Med Student Representative 2005 – 2007
- MCV Emergency Medical Student Association – President 2006 – 2007
- VCU Intramural Sports: Racquetball, Soccer, Floor Hockey 2003 – 2007
- Spider Advanced Volunteer Emergency Rescue Service (SAVERS) – Founder 1997 – 1998

CLINICAL RESEARCH EXPERIENCE – *Investigator*

- 2021 **TP-COVID001-030:** LightDeck COVID-19 Antigen Test for Point of Care
Lightdeck → TP-COVID001-030 → Device
- 2021 **TP-COVID001-012:** LightDeck COVID Total Antibody Test for Point of Care
Lightdeck → TP-COVID001-012 → Device
- 2021 **V110-911:** A Phase 3, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Concomitant Administration of Pneumococcal Vaccine and SARS-CoV-2 Vaccine in Healthy Adults 50 Years of Age or Older.
Merck → V110-911 → Phase 3
- 2021 **mRNA-1647-P301:** A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
Moderna → mRNA-1647-P301 → Phase 3
- 2021 **M18-969:** A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain
Abbvie → M18-969 → Phase 3b
- 2021 **212390:** A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
GlaxoSmithKline → 212390 → Phase 3
- 2021 **C3671008:** A Phase 3, Randomized, Double – OR Observer-blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a Respiratory Syncytial Virus (RSV) Prefusion F Subunit Vaccine in Infants Born to Women Vaccinated During Pregnancy
Pfizer → C3671008 → Phase 3
- 2021 **R10933-10987-COV-2121:** A Phase 2a, Open-Label Study Assessing Pharmacokinetics, Safety, Tolerability, And Immunogenicity of Single-Dose Subcutaneous or Intramuscular Anti-Spike (S) Sars-Cov-2 Monoclonal Antibodies (Casirivimab And Imdevimab) In High-Risk Pediatric Subjects Under 12 Years of Age
Regeneron → R10933-10987-COV-2121 → Phase 2/3
- 2021 **VAC31518COV3005:** A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Simultaneous Administration of

- Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older
JNJ/JRD → VAC31518COV3005 → Phase 3
- 2021 **mRNA-1273-P204:** A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS CoV-2 Vaccine in Healthy Children 6 months to 12 Years of Age.
Moderna → mRNA-1273-P204 → Phase 2/3
- 2021 **VAC31518COV3003:** A Randomized, Placebo-controlled Phase 3 Study to Evaluate 3 Dose Levels of Ad26.COV2.S administered as single-dose or two-dose schedules in Health Adults
Janssen Research and Development → VAC31518COV3003 → Phase 3
- 2021 **ACTIV-2/A5401:** Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID)
NIAD (National Institute of Allergy & Infectious Diseases) → ACTIV-2/A5401 → Phase 2/3
- 2021 **ADG20-PREV-001:** A Phase 2/3 Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Prevention of COVID-19 (EVADE)
Adagio → ADG20-PREV-001 → Phase 2/3
- 2020 **D8850C00003:** A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061) for Post-exposure Prophylaxis of COVID-19.
AstraZeneca → D8850C00003 → Phase 3
- 2020 **D8110C00001:** A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19
AstraZeneca → D8110C00001 → Phase 3
- 2020 **D3256C00001:** A Phase 2 Multinational, Randomized, Double-blind, Parallel-group, 16-week Placebo-controlled Study with a 36-week Extension to Investigate the Use of Benralizumab for Patients with Moderate to Severe Atopic Dermatitis Despite Treatment with Topical Medications (The HILLIER Study)
AstraZeneca → D8110C00001 → Phase 2
- 2020 **20-AVP-786-306:** A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer's type
Avanir → 20-AVP-786-306 → Phase 3
- 2020 **ARQ-151-107:** An Open Label, Phase 1, Maximal Usage Pharmacokinetics and Safety Study of ARQ-151 Cream 0.3% Administered QD in Adolescent and Adult Subjects with Chronic Plaque Psoriasis
Arcutis → ARQ-151-107 → Phase 1
- 2020 **INCB 18424-308 EXT:** A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants with Vitiligo
Incyte → INCB 18424-308 EXT → Phase 3
- 2020 **CSP-18-0002:** DERMaSensor Study of Primary Care Physician use of an adjunctive tool utilizing Elastic-Scattering Spectroscopy (ESS) on skin lesions suggestive of skin cancer (DERM-SUCCESS)

DermaSensor, Inc. → CSP-18-0002 → Device

- 2020 **FB825CLRS01:** A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate Efficacy, Pharmacokinetics, and Safety of Multiple Intravenous Doses of FB825 in Adults with Atopic Dermatitis
Fountain / Oneness Biotech Ltd. → FB825CLRS01 → Phase 2
- 2020 **AMTX100-AD-01:** A two-part, Phase I/II, Multi-center, double-blind, randomized, vehicle-controlled study of the safety and efficacy of topically applied AMTX100 CF in adult patient with mild to moderate atopic dermatitis
Amtryx Therapeutics → AMTX100-AD-01 → Phase 1/2
- 2020 **DS107G-05-AD3:** A Randomized, Double-blind, Placebo-controlled Study to assess the Efficacy and Safety of Orally Administered DS107 in Adult Patients with Moderate to Severe Atopic Dermatitis
DS Biopharma → DS107G-05-AD3 → Phase 2
- 2020 **M19-850:** A Phase 3b, open-label treatment extension study of Upadacitinib for the treatment of adult subjects with moderate to severe atopic dermatitis who completed treatment in Study M16-046
Abbvie → M19-850 → Phase 3b
- 2019 **V503-049:** A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent infection with HPV Types 16, 18, 31, 33, 45, 52, or 58 in adult males, 20 to 45 years of age
Merck → V503-049 → Phase 3
- 2019 **ARQ-151-306:** A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.3% in Subjects with Chronic Plaque Psoriasis who have Completed Preceding Studies ARQ-151-301 or ARQ-151-302
Arcutis Biotherapeutics Inc. → ARQ-151-306 → Phase 3
- 2019 **ARQ-151-302:** A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects with Chronic Plaque Psoriasis
Arcutis Biotherapeutics Inc. → ARQ-151-302 → Phase 3
- 2019 **ARQ-154-204:** A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Adolescents and Adults with Scalp and Body Psoriasis
Arcutis Biotherapeutics Inc. → ARQ-151-204 → Phase 2b
- 2019 **LIN-MD-64:** A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Safety and Efficacy Study of Linaclotide Administered Orally to Children, Ages 6 to 17 Years, With Functional Constipation (FC)
Allergan → LIN-MD-64 → Phase 3
- 2019 **LIN-MD-66:** A Phase 3, Open-label, Long-term Safety Study of Oral Linaclotide Administered to Pediatric Participants with Functional Constipation (FC) or Irritable Bowel Syndrome with Constipation (IBS-C)
Allergan → LIN-MD-66 → Phase 3
- 2019 **LIN-MD-67:** A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Sequential, Ascending, Multidose Study to Evaluate the Safety and Efficacy of Linaclotide in Pediatric Participants (Age 2 to 5 Years) with Functional Constipation
Allergan → LIN-MD-67 → Phase 2
- 2019 **M16-046:** A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermatitis.

- Abbvie → M16-046 → Phase 3b**
- 2019 **INCB 18424-307:** A Phase 3, Double-Blind, Randomized, Vehicle Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants with Vitiligo
Incyte Corporation → INCB 18424-307 → Phase 3
- 2019 **CQBW251B2201:** A 24-week multi-center, double-blind, placebo-controlled dose-range finding study to investigate the efficacy and safety of oral QBW251 in COPD patients on triple inhaled therapy (LABA/LAMA/ICS)
Novartis Pharmaceuticals → CQBW251B2201 → Phase 2b
- 2019 **APD334-201:** A Multicenter, Randomized, Double-Blinded, Placebo-Controlled 16-Week Study (with a 52-Week Open-Label Extension) to Assess the Safety and Efficacy of Etrasimod in Subjects with Moderate-to-Severe Atopic Dermatitis
Arena Pharmaceuticals, Inc. → APD334-201 → Phase 2
- 2019 **ARQ-151-212:** A Phase 2, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% and ARQ-151 Cream 0.15% Administered QD in Adolescent and Adult Subjects with Atopic Dermatitis
Arcutis, Inc. → ARQ-151-212 → Phase 2
- 2019 **CR845-210501:** A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy And Safety Of Oral Difelikefalin (Cr845) For Moderate To Severe Pruritus In Adult Subjects With Atopic Dermatitis
Cara Therapeutics Inc. → CR845-210501 → Phase 2
- 2019 **ANB020-005:** A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profile of ANB020 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis
AnaptysBio, Inc. → ANB020-005 → Phase 2b
- 2019 **CP 0418 SS-P2 051:** Open-Label Study of the Pharmacokinetics and Safety Including HPA Axis Suppression Potential of Clobetasol Topical Oil in Pediatric Subjects with Moderate to Severe Atopic Dermatitis
Hill Dermaceuticals, Inc. → CP 0418 SS-P2 051 → Phase 1/2
- 2019 **INCB 18424-103:** A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants with Atopic Dermatitis
Incyte Corporation → INCB 18424-103 → Phase 1
- 2019 **V01-124A-501:** A Phase 1b, Open-Label Randomized Study Evaluating the Safety and Systemic Pharmacokinetics of Topically Applied IDP-124 Lotion in Pediatric Subjects with Atopic Dermatitis under Maximal Use Conditions
Bausch Health → V01-124A-501 → Phase 1b
- 2019 **RD.03.SPR.118169:** A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate to Severe Atopic Dermatitis
Galderma → RD.06.SPR.118169 → Phase 3
- 2019 **RD.06.SPR.116912:** A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics and Safety of Nemolizumab (CD14152) in Adolescent Subjects (12-17 years) with Moderate-to-Severe Atopic Dermatitis and Associated Pruritus
Galderma → RD.06.SPR.116912 → Phase 2
- 2019 **ASN002AD-201-EXT:** A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the long-term Safety, Tolerability and Efficacy of ASN002 in Subjects with Moderate to Severe Atopic Dermatitis.
ASANA → ASN002AD-201-EXT → Phase 2

- 2018 **ASN002AD-201:** A Randomized, Double-Blind, Placebo-Controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects with Moderate to Severe Atopic Dermatitis CODE NUMBER: ASN002AD-201 (RADIANT) **ASANA → ASN002AD-201 → Phase 2b**
- 2019 **GS40868:** A phase II open-label extension study to evaluate the long-term safety and efficacy of Fenebrutinib in patients previously enrolled in a Fenebrutinib chronic spontaneous urticaria study
Genentech → GS40868 → Phase 2
- 2019 **GS39684:** A Phase II, multicenter, randomized, double-blind, placebo-controlled pilot and dose-ranging study of GDC-0853 in patients with refractory chronic spontaneous Urticaria (CSU)
Genentech → GS39684 → Phase 2
- 2019 **R3500-AD-1798:** A randomized, double-blind, placebo-controlled, phase 2A study to assess the efficacy and safety of REGN3500 monotherapy and combination of REGN3500 plus Dupilumab in adult patients with moderate-to-severe atopic dermatitis **Regeneron → R3500-AD-1798 → Phase 2a**
- 2019 **INCB 18424-304:** A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults with Atopic Dermatitis
INCYTE → INCB 18424-304 → Phase 3
- 2019 **MVT-601-035:** An International Phase 3 Double-Blind, Placebo-controlled, Randomized Withdrawal Study of Relugolix Co-administered with Estradiol and Norethindrone Acetate in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids
Myovant Sciences → MVT-601-035 → Phase 3
- 2019 **GS40965:** A Phase II, randomized, double blind, placebo controlled multicenter study to assess the efficacy and safety of MSTT1041A in patients with moderate to severe atopic dermatitis
Genentech → GS40965 → Phase 2
- 2019 **MTI-107:** An open-label long-term safety study of Serlopitant for the treatment of pruritis
Menlo → MTI-107 → Phase 3
- 2019 **EX9536-4388:** SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity. IND# 126 360
Novo Nordisk → EX9536-4388 → Phase 3b
- 2019 **C3718-302:** A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients with Gastroesophageal Reflux Disease while receiving Proton Pump Inhibitors
Ironwood → C3718-302 → Phase 2
- 2019 **GBR 830-204:** A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of GBR 830 in Adult Subjects with Moderate to Severe Atopic Dermatitis
Glenmark Pharmaceuticals → GBR 830-204 → Phase 2b
- 2019 **FLSA-P100/50-PVCL-2:** A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100µg and Salmeterol Xinafoate 50µg Inhalation Powder Compared with Advair Diskus® 100/50 in Subjects with Asthma
West-Ward Columbus Inc. → FLSA-P100/50-PVCL-2 → Phase Bioequivalence
- 2019 **NN9536-4376:** Protocol Title: Effect and safety of Semaglutide 2.4 mg once-weekly in subjects with overweight or obesity who have reached target dose during run-in period
Novo Nordisk → NN9536-4376 → Phase 3a

- 2019 **D5180C00007**: A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma (NAVIGATOR)
AstraZeneca → **D5180C00007** → **Phase 3**
- 2019 **MVT-601-3002**: LIBERTY 2: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co-Administered with and without Low-Dose Estradiol and Norethindrone Acetate in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids
MYOVANT → **MVT-601-3002** → **Phase 3**
- 2019 **PT001102**: A Randomized, Double-Blind, Parallel Group, Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects with Persistent Asthma
Pearl Therapeutics → **PT001102** → **Phase 2/3**
- 2019 **K-877-302**: Pemafibrate to Reduce cardiovascular Outcomes by reducing triglycerides IN patients with diabetes (PROMINENT)
Kowa Research Institute, Inc. → **K-877-302** → **Phase 3**
- 2018 **KPL-716-C001**: A Phase Ib, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Repeated Doses of KPL-716
Kiniksa → **KPL-716-C001** → **Phase 1b**
- 2018 **MVT-601-3003 LIBERTY EXTENSION**: An International Phase 3 Open-Label, Single-Arm, Long-Term Efficacy and Safety Extension Study to Evaluate Relugolix Co- Administered with Low-Dose Estradiol and Norethindrone Acetate in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids
Myovant → **MVT-601-3003** → **Phase 3**